TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
+47.93%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$1.08B
AUM Growth
+$1.08B
(+53%)
Cap. Flow
+$243M
Cap. Flow
% of AUM
22.47%
Top 10 Holdings %
Top 10 Hldgs %
41.77%
Holding
136
New
30
Increased
24
Reduced
21
Closed
13
Top Buys
Top Sells
| 1 |
EQRX
EQRx, Inc. Common Stock
EQRX
|
$22.4M |
| 2 |
THRD
Third Harmonic Bio
THRD
|
$11.5M |
| 3 |
NovoCure
NVCR
|
$7.95M |
| 4 |
Intellia Therapeutics
NTLA
|
$6.02M |
| 5 |
BioCryst Pharmaceuticals
BCRX
|
$5.99M |
Sector Composition
| 1 | Healthcare | 95.77% |
| 2 | Financials | 3.5% |
| 3 | Real Estate | 0.65% |
| 4 | Technology | 0.08% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $91.5M | 8.46% | 1,558,059 +1,378,059 | +766% | +$81M |
|
|
IMGN
2
DELISTED
Immunogen Inc
IMGN
| $65.2M | 6.02% | 2,199,137 +699,137 | +47% | +$20.7M |
|
3
Tarsus Pharmaceuticals
TARS
$2.47B
| $44.6M | 4.13% | 2,204,797 +64,211 | +3% | +$1.3M |
|
4
KalVista Pharmaceuticals
KALV
$678M
| $42.1M | 3.89% | 3,440,345 | – | – |
|
|
LIAN
5
DELISTED
LianBio American Depositary Shares
LIAN
| $41.9M | 3.87% | 9,366,783 +7,566,783 | +420% | +$33.8M |
|
6
AnaptysBio
ANAB
$569M
| $41.8M | 3.86% | 1,950,609 | – | – |
|
7
Mirum Pharmaceuticals
MIRM
$3.71B
| $33.6M | 3.1% | 1,137,107 | – | – |
|
8
Evolus
EOLS
$494M
| $32.6M | 3.01% | 3,097,399 | – | – |
|
9
Altimmune
ALT
$338M
| $30.9M | 2.86% | 2,750,000 | – | – |
|
10
Immunocore
IMCR
$1.62B
| $27.7M | 2.56% | 405,600 | – | – |
|
11
Axsome Therapeutics
AXSM
$6.05B
| $25.5M | 2.35% | 320,000 | – | – |
|
12
PTC Therapeutics
PTCT
$3.92B
| $24.8M | 2.29% | +900,000 | New | +$24.8M |
|
|
GRCL
13
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $22M | 2.03% | 2,191,417 +2,032,330 | +1,277% | +$20.4M |
|
14
Revolution Medicines
RVMD
$7.1B
| $19.5M | 1.8% | +679,630 | New | +$19.5M |
|
15
Vaxcyte
PCVX
$4B
| $18.8M | 1.74% | 300,000 | – | – |
|
16
Eli Lilly
LLY
$657B
| $17.5M | 1.62% | 30,000 | – | – |
|
|
FLG
17
Flagstar Financial, Inc.
FLG
$5.33B
| $16.4M | 1.52% | 1,606,600 | – | – |
|
|
ITCI
18
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $15.8M | 1.46% | 220,000 -80,000 | -27% | -$5.73M |
|
|
ONC
19
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $15.3M | 1.42% | 85,000 | – | – |
|
|
AVDL
20
Avadel Pharmaceuticals
AVDL
$1.43B
| $15.2M | 1.41% | 1,079,528 +79,528 | +8% | +$1.12M |
|
21
Viridian Therapeutics
VRDN
$1.5B
| $15.1M | 1.39% | 692,925 +23,800 | +4% | +$518K |
|
22
CRISPR Therapeutics
CRSP
$4.71B
| $13.5M | 1.24% | +215,000 | New | +$13.5M |
|
|
THRX
23
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
| $13.2M | 1.22% | +3,255,026 | New | +$13.2M |
|
24
Atea Pharmaceuticals
AVIR
$267M
| $12.4M | 1.15% | 4,076,741 +476,741 | +13% | +$1.45M |
|
25
AstraZeneca
AZN
$248B
| $11.4M | 1.06% | 170,000 | – | – |
|